Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
The following are the top stories on the business pages of British newspapers. The Times - The UK is losing out on investment from AstraZeneca Plc to more competitive countries, Tom Keith-Roach, the head of the company, warned. - A British semiconductor company, IQE Plc could move overseas unless the government sets out its strategy for the sector in the next six months, its chief executive said.
Astrazeneca (AZN) closed the most recent trading day at $63.15, moving -0.65% from the previous trading session.